
NYSEHealthcareMedical - Instruments & Supplies
最新資料
US$17.145
−US$0.195 · -1.12%
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
一般交易時段
US$17.145
−US$0.195 · -1.12%
盤中時間採用ET。市場資料可能有所延遲。
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
日內區間
目前US$17.145
52週區間
目前US$17.145
盤中時間採用ET。市場資料可能有所延遲。
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
日內區間
目前US$17.145
52週區間
目前US$17.145
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 51.01億 USD | 47.91億 USD | 41.46億 USD | 37.68億 USD | 37.65億 USD |
| 銷貨成本 | 23.08億 USD | 18.72億 USD | 16.42億 USD | 15.19億 USD | 14.67億 USD |
| 毛利 | 27.93億 USD | 29.19億 USD | 25.04億 USD | 22.49億 USD | 22.98億 USD |
| 研究與開發 | 3.71億 USD | 3.43億 USD | 3.24億 USD | 3.07億 USD | 2.71億 USD |
| 銷售、一般及管理費用 | 22.34億 USD | 20.82億 USD | 17.36億 USD | 14.78億 USD | 13.89億 USD |
| 營業費用 | 26.05億 USD | 27.57億 USD | 23.74億 USD | 20.42億 USD | 19.69億 USD |
| 利息收入 | 1200萬 USD | 1500萬 USD | 1500萬 USD | 600萬 USD | — |
| 利息支出 | 4.31億 USD | 3.99億 USD | 2.83億 USD | 1.46億 USD | — |
| 折舊和攤銷 | 4.21億 USD | 4.36億 USD | 3.82億 USD | 3.79億 USD | 4.15億 USD |
| 營業利益 | 1.88億 USD | 1.62億 USD | 1.3億 USD | 2.07億 USD | 3.29億 USD |
| 淨利 | −3.6億 USD | −3.17億 USD | −2.6億 USD | 600萬 USD | 1.82億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$20.83
上漲空間 21.49%報告持有此股票曝險的交易所交易基金。
Ballast Small/Mid Cap ETFMGMT243.63萬1.48%1.67億 USD1.17%US$49.11-0.05%
Dimensional World ex U.S. Core Equity 2 ETFDFAX26.33萬0.00%123.72億 USD0.28%US$36.87-0.57%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN15.76萬0.04%3.51億 USD0.47%US$45.34-0.81%
Gotham 1000 Value ETFGVLU10.5萬0.04%2.44億 USD0.65%US$27.205+0.09%
Dimensional - International Core Equity 2 ETFDFIC4.44萬0.00%150.1億 USD0.22%US$37.265-0.20%
BNY Mellon US Small Cap Core Equity ETFBKSE2.89萬0.03%8355.66萬 USD0.04%US$41.62-0.00%
Ballast Small/Mid Cap ETFMGMT
Dimensional World ex U.S. Core Equity 2 ETFDFAX
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN
Gotham 1000 Value ETFGVLU
Dimensional - International Core Equity 2 ETFDFIC
BNY Mellon US Small Cap Core Equity ETFBKSEAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。